| > This disease is novel in ways that no other disease is. It is a novel disease, but it is close to SARS-CoV-1 from the 2003 outbreak. There is a lot of long-term research on the quality of life indicators. One paper listed 20% of hospitalized with full disability due to chronic fatigue syndrome 5 years after hospitalization. Young people with viral pneumonia and mechanical ventilation still walked slower than 60+ seniors (very little restoration of lung capacity). > a large percentage of those who get it will experience life-long adverse effects Mental health also influences QOLI. From SARS, MERS, HIV, and other severe viral infections, we know that this can have severe impact on mental health (many from SARS-CoV-1 and MERS suffer from PTSD and depression if not degenerative bone necrosis == constant muscle pain). People report trouble smelling or speaking months after COVID. There are support groups popping up for people with persistent problems, chronic fatigue and sleep problems being one that seems to linger for months. Early research from Italy: > Patients were assessed a mean of 60.3 (SD, 13.6) days after onset of the first COVID-19 symptom; at the time of the evaluation, only 18 (12.6%) were completely free of any COVID-19–related symptom, while 32% had 1 or 2 symptoms and 55% had 3 or more. None of the patients had fever or any signs or symptoms of acute illness. Worsened quality of life was observed among 44.1% of patients. [...] a high proportion of individuals still reported fatigue (53.1%), dyspnea (43.4%), joint pain, (27.3%) and chest pain (21.7%). |